

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7318313

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KYUNG SUN KIM	04/14/2022
JEONG-AH KIM	04/14/2022
ANNA MOON	04/14/2022
DONGKEUN SONG	04/14/2022
JUYOUNG JUNG	04/14/2022
JUN-SU BAN	04/14/2022
SOO-JIN LEE	04/14/2022
YOONSUK LEE	04/14/2022
RECEIVING PARTY DATA	
Name:	ILDONG PHARACEUTICAL CO., LTD.
Street Address:	2, BAUMOE-RO 27-GIL
Internal Address:	SEOCHO-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	06752
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17548279
CORRESPONDENCE DATA	
Fax Number:	(650)938-5200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6503357184
Email:	cmedina@fenwick.com
Correspondent Name:	GLENN J. FOULDS
Address Line 1:	FENWICK & WEST LLP
Address Line 2:	801 CALIFORNIA STREET
Address Line 4:	MOUNTAIN VIEW, CALIFORNIA 94041
ATTORNEY DOCKET NUMBER:	37448-47497/US (010US)
NAME OF SUBMITTER:	GLENN J. FOULDS; REG. NO. 64714

PATENT

SIGNATURE:	/Glenn J. Foulds/
DATE SIGNED:	05/06/2022
Total Attachments: 4 source=47497_US_Assignment_FULLY_EXECUTED#page1.tif source=47497_US_Assignment_FULLY_EXECUTED#page2.tif source=47497_US_Assignment_FULLY_EXECUTED#page3.tif source=47497_US_Assignment_FULLY_EXECUTED#page4.tif	

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to ILDONG PHARMACEUTICAL CO., LTD., a corporation of the Republic of Korea, having a place of business at 2, Baumce-ro 27-gil, Seocho-gu, Seoul, Republic of Korea, 06752 ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional or non-provisional application(s), including those filed under 35 U.S.C. § 111, design applications filed under 35 U.S.C. § 171, Registered Community Designs, international applications filed according to the Patent Cooperation Treaty (PCT), U.S. national phase applications filed under 35 U.S.C. § 371, national or regional applications filed in any other country throughout the world, and any patents issuing thereon ("PATENT RIGHTS"):

- U.S. Application No. 17/548,279, entitled NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR, filed on December 18, 2021, which claims priority from a provisional application, filed on December 11, 2020, now bearing U.S. Application No. 63/124,615; and
- PCT Application No. PCT/US2021/062942, entitled NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBIT, filed on December 18, 2021, which claims priority from a provisional application, filed on December 11, 2020, now bearing U.S. Application No. 63/124,615

2. The entire worldwide right, title, and interest in and to:

(a) the PATENT RIGHTS, including any right of priority; (b) any provisional, divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom together with all rights to recover damages for infringement of provisional rights.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

Title:	NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR		
Filed:	December 10, 2021	Attorney Docket #:	37448-47497/US (010US)
Application #:	17/548,279		

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date: 2022 / April / 14


Xoon-Suk LEE

Date: 2022 / 04 / 14


Kyung Sun KIM

Date: 2022 / 04 / 14


Jeong-Ah KIM

Date: 2022 / 04 / 14



Anna MOON

Title:	NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR		
Filed:	December 10, 2021	Attorney Docket #:	37443-47497/US (01QUS)
Application #:	17/548,279		

Date: 2022/04/14


Dongkeun SONG


Date: 2022/04/14


Juyoung JUNG

Date: 2022/04/14


Jun-Su BAN

Date: 2022/04/14


Soo-Jin LEE

Title:	NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR		
Filed:	December 10, 2021	Attorney Docket #:	37448-47497/US (010US)
Application #:	17/548,279		

ASSIGNEE HEREBY ACCEPTS THIS ASSIGNMENT:

Date: 2022/ 4 / 14

ILDONG PHARMACEUTICAL CO., LTD.

Signature: Paul W. Yun

Name: PAUL WOONGSUP YUN

Title: CEO